Abstract | BACKGROUND: METHODS: BRAIN was a phase II, multicenter, randomized, noncomparative trial of BEV alone (n = 85) or in combination with irinotecan (CPT-11) (n = 82) in adults with recurrent glioblastoma. Median corticosteroid dose for patients who used corticosteroids at baseline was summarized by treatment arm; the percentage of patients who had sustained (≥50% corticosteroid dose reduction for ≥50% of time on study drug) or complete (discontinuation of corticosteroid for ≥25% of time on study drug) reduction in corticosteroid dose overall and by objective response and progression-free survival was calculated. The incidence of corticosteroid-related adverse events was summarized. RESULTS: In each treatment group, 50% of patients were using systemic corticosteroids at baseline. The majority of those experienced a reduction in dose while receiving BEV-based therapy. Thirteen (30.2%) BEV and 20 (46.5%) BEV + CPT-11 patients had a sustained reduction of corticosteroid dose; 7 (16.3%) BEV and 9 (20.9%) BEV + CPT-11 patients had a complete reduction of corticosteroid dose. The majority of patients who had an objective response or progression-free survival >6 months experienced corticosteroid dose reduction. Approximately 64% of patients who used corticosteroids while receiving BEV-based therapy experienced infection. CONCLUSION: BEV may have corticosteroid-sparing effects in patients with recurrent glioblastoma. Corticosteroid reduction may positively affect patient health-related quality of life. Given the exploratory nature of the analyses in a noncomparative study, these results should be interpreted cautiously.
|
Authors | James J Vredenburgh, Timothy Cloughesy, Meghna Samant, Michael Prados, Patrick Y Wen, Tom Mikkelsen, David Schiff, Lauren E Abrey, W K Alfred Yung, Nina Paleologos, Martin K Nicholas, Randy Jensen, Asha Das, Henry S Friedman |
Journal | The oncologist
(Oncologist)
Vol. 15
Issue 12
Pg. 1329-34
( 2010)
ISSN: 1549-490X [Electronic] England |
PMID | 21147867
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Adrenal Cortex Hormones
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Vascular Endothelial Growth Factor A
- Bevacizumab
|
Topics |
- Adrenal Cortex Hormones
(therapeutic use)
- Adult
- Angiogenesis Inhibitors
(therapeutic use)
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Brain Neoplasms
(drug therapy, pathology)
- Female
- Glioblastoma
(drug therapy, pathology)
- Humans
- Lymphatic Metastasis
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy, pathology)
- Neoplasm Staging
- Salvage Therapy
- Survival Rate
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors, metabolism)
|